These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V. AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387 [Abstract] [Full Text] [Related]
5. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM. J Clin Virol; 2007 Jan 02; 38(1):32-8. PubMed ID: 17064957 [Abstract] [Full Text] [Related]
6. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group. Antivir Ther; 2005 Jan 02; 10(2):309-17. PubMed ID: 15865225 [Abstract] [Full Text] [Related]
8. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C. J Viral Hepat; 2008 Jul 02; 15(7):482-9. PubMed ID: 18221297 [Abstract] [Full Text] [Related]
9. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. J Gastroenterol Hepatol; 2007 Jun 02; 22(6):832-6. PubMed ID: 17565637 [Abstract] [Full Text] [Related]
10. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V. J Viral Hepat; 2008 Oct 02; 15(10):710-5. PubMed ID: 18637070 [Abstract] [Full Text] [Related]
11. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ. J Viral Hepat; 2010 Dec 02; 17(12):834-8. PubMed ID: 20196800 [Abstract] [Full Text] [Related]
12. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Liver Transpl; 2008 Jan 02; 14(1):53-8. PubMed ID: 18161839 [Abstract] [Full Text] [Related]
13. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V. J Viral Hepat; 2007 Jun 02; 14(6):387-91. PubMed ID: 17501758 [Abstract] [Full Text] [Related]
14. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. Napoli N, Giannelli G, Antonaci A, Antonaci S. J Viral Hepat; 2008 Apr 02; 15(4):300-4. PubMed ID: 18307592 [Abstract] [Full Text] [Related]
15. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V. Antivir Ther; 2005 Apr 02; 10(5):657-62. PubMed ID: 16152759 [Abstract] [Full Text] [Related]
16. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044 [Abstract] [Full Text] [Related]
17. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M. Biomed Pharmacother; 2011 Jul 28; 65(4):303-6. PubMed ID: 21723079 [Abstract] [Full Text] [Related]
18. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA. J Viral Hepat; 2008 Aug 28; 15(8):591-9. PubMed ID: 18482284 [Abstract] [Full Text] [Related]
19. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group. Antivir Ther; 2007 Aug 28; 12(4):469-76. PubMed ID: 17668555 [Abstract] [Full Text] [Related]
20. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J. J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276 [Abstract] [Full Text] [Related] Page: [Next] [New Search]